dostęp otwarty
Farmakologiczne leczenie choroby Alzheimera — współczesne możliwości
- Klinika Psychiatrii Rozwojowej, Zaburzeń Psychotycznych i Wieku Podeszłego Gdański Uniwersytet Medyczny, Srebrniki 1,, 80-282 Gdańsk, Polska
dostęp otwarty
Streszczenie
Streszczenie
Słowa kluczowe
choroba Alzheimera farmakoterapia, current trends
Tytuł
Farmakologiczne leczenie choroby Alzheimera — współczesne możliwości
Czasopismo
Numer
Typ artykułu
Artykuł przeglądowy
Strony
87-94
Opublikowany online
2020-05-30
Wyświetlenia strony
1606
Wyświetlenia/pobrania artykułu
1259
DOI
Rekord bibliograficzny
Psychiatria 2020;17(2):87-94.
Słowa kluczowe
choroba Alzheimera farmakoterapia
current trends
Autorzy
Leszek Bidzan
- https://www.alz.co.uk/research/statistics.
- Hurd MD, Martorell P, Langa K, et al. Monetary costs of dementia in the United States. N Engl J Med. 2013; 368(14): 1326–1334.
- Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci Ther. 2010; 16(4): 235–245.
- Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982; 217(4558): 408–414.
- Fariss MW, Mumaw VR, Walton LP. Tetrahydroaminoacridine-induced apoptosis in rat hepatocytes. Toxicol In Vitro. 1996; 10(4): 383–393.
- Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014; 6(4): 37.
- Ondrejcak T, Klyubin I, Hu NW, et al. Alzheimer's disease amyloid beta-protein and synaptic function. Neuromolecular Med. 2010; 12(1): 13–26.
- Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56(9): 1154–1166.
- O'Regan J, Lanctôt KL, Mazereeuw G, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003; 169(6): 557–564.
- National Institute for Clinical Excellence [NICE]. Appaisal consultation document: Alzheimer's disease — Donepezil, rivastigmine, galantamine and memantine. London: NICE; 2006. http://www.nice.org.uk/page.
- Iliffe S. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease. CNS Drugs. 2007; 21(3): 177–184.
- Birks JS, Harvey RJ, Birks JS, et al. Tacrine for Alzheimer's disease. Cochrane Database Syst Rev. 2000; 7(2): CD000202–369.
- Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005; 20(5): 459–464.
- Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006; 14(8): 704–715.
- Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009; 1(2): 7.
- Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007; 24(1): 20–27.
- Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008; 69(3): 341–348.
- https://www.alzforum.org/news/community-news/senate-approves-234-billion-budget-alzheimers-research.
- Cummings J, Reynders R, Zhong K. Globalization of Alzheimer's disease clinical trials. Alzheimers Res Ther. 2011; 3(4): 24.
- Młynarczyk R, Bochon B, Piontek A, et al. Choroba Alzheimera — nowe strategie leczenia. Psychiatria. 2016; 13(4): 210–214.
- Elmaleh DR, Farlow MR, Conti PS, et al. Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions. J Alzheimers Dis. 2019; 71(3): 715–732.
- Hu X, Das B, Hou H, et al. BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. J Exp Med. 2018; 215(3): 927–940.
- Egan MF, Mukai Y, Voss T, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. N Engl J Med. 2018; 378(18): 1691–1703.
- Egan MF, Voss T, Mukai Y, et al. Results from the APECS trial. J Prev Alzheimers Dis. 2018; 5: S1.
- Vellas B, Bain LJ, Touchon J, et al. Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018. J Prev Alzheimers Dis. 2019; 6(3): 198–203.
- Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400(6740): 173–177.
- Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature. 2002; 415(6871): 462.
- Wang CYi, Wang PN, Chiu MJ, et al. UB-311, a novel UBITh amyloid β peptide vaccine for mild Alzheimer's disease. Alzheimers Dement (N Y). 2017; 3(2): 262–272.
- De Felice FG, Vieira MNN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A. 2009; 106(6): 1971–1976.
- Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis. 2008; 13(3): 323–331.
- Persson T, Popescu BO, Cedazo-Minguez A. Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail? Oxid Med Cell Longev. 2014; 2014: 427318.
- Morales I, Guzmán-Martínez L, Cerda-Troncoso C, et al. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci. 2014; 8: 112.
- Geldenhuys WJ, Darvesh AS. Pharmacotherapy of Alzheimer's disease: current and future trends. Expert Rev Neurother. 2015; 15(1): 3–5.
- Baker LD, Espeland MA, Rapp SR. Cocoa supplement and multivitamin outcomes study of cognitive functin (COSMOS-MIND): Design of a large randomized clinical trial. J Prev Alzheimers Dis. 2018; 5(suppl_1): S20.
- Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5(6): 493–506.
- Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci. 2007; 12: 4839–4854.
- Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today. 2007; 12(5-6): 218–224.
- Letenneur L, Proust-Lima C, Le Gouge A, et al. Flavonoid intake and cognitive decline over a 10-year period. Am J Epidemiol. 2007; 165(12): 1364–1371.
- Yusufov M, Weyandt LL, Piryatinsky I. Alzheimer's disease and diet: a systematic review. Int J Neurosci. 2017; 127(2): 161–175.
- Xiao S, Zhang Z, Geng M. Phase 3 clinical trial for a novel oligosaccharide targeting multiple A-beta fragments in patients with mild-moderate AD in China J Prev Alzheimers Dis. 2018; 5: S10.
- Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2015; 86(12): 1299–1306.
- Schöll M, Lockhart SN, Schonhaut DR, et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016; 89(5): 971–982.
- Wisman LAB, Sahin G, Maingay M, et al. Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory. J Neurosci. 2008; 28(31): 7797–7807.
- Millan MJ, Di Cara B, Dekeyne A, et al. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem. 2007; 100(4): 1047–1061.
- Kumar U, Patel SC. Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain. Brain Res. 2007; 1131(1): 187–196.
- Reid RT, Sabbagh MN. Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro. J Neural Transm (Vienna). 2008; 115(10): 1437–1444.
- Kenney JW, Gould TJ. Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol. 2008; 38(1): 101–121.
- Placzek AN, Zhang TA, Dani JA. Nicotinic mechanisms influencing synaptic plasticity in the hippocampus. Acta Pharmacol Sin. 2009; 30(6): 752–760.
- Shearman E, Rossi S, Szasz B, et al. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res Bull. 2006; 69(2): 204–213.
- Geldenhuys WJ, Darvesh AS. Pharmacotherapy of Alzheimer's disease: current and future trends. Expert Rev Neurother. 2015; 15(1): 3–5.
- Atri A, Shaughnessy LW, Locascio JJ, et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008; 22(3): 209–221.
- Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009; 80(6): 600–607.
- Cummings JL, Schneider E, Tariot PN, et al. Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006; 67(1): 57–63.
- Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008; 5(1): 83–89.
- Parsons CG, Danysz W, Dekundy A, et al. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res. 2013; 24(3): 358–369.
- Shua-Haim J, Smith J, Picard F, et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Clin Drug Investig. 2008; 28(6): 361–374.
- Atri A, Molinuevo JL, Lemming O, et al. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013; 5(1): 6.
- Barik J, Wonnacott S. Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol Pharmacol. 2006; 69(2): 618–628.
- Geerts H. Indicators of neuroprotection with galantamine. Brain Res Bull. 2005; 64(6): 519–524.
- Patel L, Grossberg GT. Combination therapy for Alzheimer's disease. Drugs Aging. 2011; 28(7): 539–546.
- Schmidtke K, Holthoff V, Kressig RW, et al. Combination of Memantine and cholinesterase inhibitors in the treatment of AD. Neurology News. 2011; 1: 1–8.
- Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res. 2009; 6(2): 86–96.
- Bencherif M, Lippiello PM. Alpha7 neuronal nicotinic receptors: the missing link to understanding Alzheimer's etiopathology? Med Hypotheses. 2010; 74(2): 281–285.
- Zeng HD, Zhang Y, Peng L. Nicotine and amyloid formation. Biol Psychiatry. 2001; 49(3): 248–257.
- Karolczak D, Sawicka E, Dorszewska J, et al. Memantine - neuroprotective drug in aging brain. Pol J Pathol. 2013; 64(3): 196–203.
- Hirano K, Fujimaki M, Sasazawa Y, et al. Neuroprotective effects of memantine via enhancement of autophagy. Biochem Biophys Res Commun. 2019; 518(1): 161–170.